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Abstract
High vascular morbidity and mortality is associated with acromegaly. The aim of the present study was to assess the effects of
octreotide therapy on several known cardiovascular risk factors and to correlate them with octreotide-induced hormonal changes.
Lipid levels, LDL particle size distribution as evaluated by single vertical spin density gradient ultracentrifugation, apolipoproteins
AI and B, lipoprotein (a) [Lp(a)] concentrations and apo(a) phenotypes were evaluated in 20 non-diabetic acromegalic patients (6
M, 14 F), with normal thyroid, adrenal and gonadal function, aged 29–66 years. Normal subjects (20), matched for age, sex and
BMI served as control for lipid variables. Acromegalic patients were characterized by lower HDL cholesterol (and apoA-I) and
by higher Lp(a) concentrations in comparison to controls. Treatment with octreotide (100 mg t.i.d. for 3 months) led to: an
increase in HDL cholesterol (median: 22%), a decrease in LDL cholesterol (14%) and a decrease of the Lp(a) levels (all
phenotypes) (28%). The expected decreases of IGF-I levels (median: 48%) and 7-h AUC of GH (50%), insulin (40%),
and glucagon (20%) were observed. Only Lp(a) modifications showed a correlation with GH modifications. The study of LDL
physical properties showed that acromegalic patients had smaller and:or more dense LDL particles, in comparison with normal
controls (relative flotation rate, Rf: 0.4090.03 versus 0.4290.02 PB0.05), an alteration that might contribute to the high
vascular risk of acromegalic patients. However, the LDL subfraction distribution remained unmodified during octreotide therapy
(Rf 0.3990.03). In conclusion, this study shows that in acromegalic patients octreotide treatment is indeed associated with an
amelioration of some lipoprotein parameters, i.e. LDL, HDL, and Lp(a) concentrations. However, this treatment has no effect on
the small and:or dense LDL particles present in these patients. © 2000 Elsevier Science Ireland Ltd. All rights reserved.
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1. Introduction
Acromegaly is a rare and serious disease associated
with an increased cardiovascular mortality [1,2]. For
this reason the effects on the cardiovascular risk factors
induced by the medical therapy of this disease must be
thoroughly evaluated. Octreotide is the most widely
investigated and most frequently used somatostatin
analogue in the treatment of acromegaly.
Our previous experience, involving a large number of
acromegalic patients from all over Italy, seemed to
indicate that octreotide, besides decreasing GH and
IGF-I concentrations, had also beneficial effects on
lipid levels [3]. In fact, a significant decrease of both
total and LDL cholesterol was observed after 3 months
of octreotide treatment. However, besides LDL choles-
terol concentrations, it is now well recognized that the
LDL physical characteristics are important, a predomi-
nance of small, dense LDL particles being associated
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with increased vascular risk [4,5]. Recent data suggest
that GH excess has a direct effect on LDL subfraction
distribution [6]; however, no data exist about the possi-
ble effects of therapy, and in particular of octreotide,
on LDL size and density.
Increased circulating concentrations of lipoprotein(a)
[Lp(a)] may represent an independent risk factor for
cardiovascular disease in acromegaly. In fact, although
the mechanism by which Lp(a) influences cardiovascu-
lar morbidity is largely unknown, several epidemiologi-
cal studies have shown an association between coronary
heart disease incidence and Lp(a) levels above a
threshold concentration of 20–30 mg:dl [7–9]. Lp(a)
shows considerable size variation (from :300 to :
800 KDa) among individuals owing to different num-
bers of cysteine-rich sequences (homologous to
plasminogen kringle 4) in the apolipoprotein(a)
[apo(a)], resulting in different apo(a) phenotypes. The
serum concentrations of Lp(a) are inversely related to
its size, which is genetically determined. Although it is
widely accepted that GH has important effects in in-
creasing Lp(a) concentrations [10,11], it is not known if
all apo(a) phenotypes are equally sensitive to GH
modifications.
The aim of the present study was to assess the effects
of octreotide therapy on LDL physical properties, and
on lipoprotein and Lp(a) levels (in relation also to the
apo(a) phenotype) and to correlate them with hormonal
and metabolic changes induced by the therapy. A sec-
ondary objective was to verify if acromegaly, non-com-
plicated by diabetes, is associated with modifications of
these lipid parameters.
2. Materials and methods
2.1. Design
Open, multicentric prospective study. The study was
approved by the local ethics committees and written
informed consent was obtained from all patients.
2.2. Subjects
Patients (20) with active acromegaly (as shown by
elevated serum IGF-I levels and serum GH not sup-
pressible by glucose load) (14 women, six men), aged
29–66 years (mean9SD46910 years), were re-
cruited. Ten patients had been previously submitted to
unsuccessful adenomectomy, followed in one case by
conventional pituitary radiotherapy and in seven cases
by medical therapy with bromocriptine (three patients)
and:or somatostatin analogs (seven patients) that was
discontinued 1 or more months prior to the start of this
study.
Only patients with normal thyroid, adrenal and go-
nadal functions were admitted to the study, and none
of the patients was taking drugs known to influence
lipid metabolism, including estrogen-containing drugs
or hypoglycaemic agents. Patients with known diabetes
mellitus were excluded, and all patients had fasting
glucose levels below 110 mg:dl and normal glycated
hemoglobin levels. When considering glucose response
to OGTT, however, four patients showed an impaired
glucose tolerance according to the criteria of the Expert
Committee of the American Diabetes Association [12].
A group of 20 subjects, matched for age, sex and
BMI (2492 Kg:m2) served as control for lipid
variables.
2.3. Design of the study
Clinical and biochemical evaluations were performed
at baseline and after 3 months of therapy with oc-
treotide (Longastatina®, Italfarmaco S.p.A.), 100 mg
t.i.d. sc under controlled dietary conditions. Pre-treat-
ment studies included the following tests: a 4-h OGTT
(75 g orally, to confirm active acromegaly) and a 7-h
saline infusion, with a light, standardized meal of about
600 kcal given at 4 h, for GH, insulin, glucagon and
glucose assay. IGF-I and lipid parameter measurements
were done on two basal samples taken on 2 different
days. After 3 months of therapy, the same 7-h study
giving octreotide 100 mg sc at time 0 and, on a different
day, OGTT, giving glucose 2-h after octreotide sc injec-
tion, were carried out. Additionally, serum levels of
TSH, free T3, free T4, and, in the women, estrogen and
progesterone, together with routine laboratory bio-
chemical analysis, were also evaluated.
2.4. Analytical methods
All lipid assays were performed at the lipoprotein
laboratory in the Department of Internal Medicine,
University of Padova.
Cholesterol [13], HDL cholesterol [14], and triglyce-
rides [15] were measured by standard methods. The
coefficient of variation (CV), intra-assay and inter-as-
say, for total cholesterol were 1.0 and 1.2%, respec-
tively, for triglycerides 1.5% and 2.5%, for HDL
cholesterol 1.2% and 1.5%. LDL cholesterol levels were
calculated using the equation of Friedewald [16].
LDL distribution and flotation properties were evalu-
ated by single vertical spin density gradient ultracen-
trifugation (SVS-DGUC) using a modification of the
method described by Chung et al. [17,18]. One aliquot
of 1 ml of plasma adjusted to a density of 1.080 g:ml
(final volume 4 ml), was layered underneath 9 ml of a
1.006 g:ml NaCl solution, producing a discontinuous
salt gradient in a Beckman VTi 65.1 vertical rotor
(Beckman Instruments, Inc., Palo Alto, CA, USA).
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Samples were centrifuged at 65 000 rpm for 70 min
(total t2 2.361011) at 5°C; the tubes were then
fractionated (Fraction Recovery System by Beckman
Instruments, Palo Alto, CA, USA) from the bottom at
a flow rate of 1.7 ml:min, and 37 0.35-ml fractions were
collected. Total cholesterol was measured in each frac-
tion. The relative flotation rate (Rf), which character-
izes LDL peak buoyancy, was obtained by dividing the
fraction number containing the LDL-cholesterol peak
by the total number of fractions collected. The CV for
LDL Rf was 1.1% intra-assay and 1.7% inter- assay.
Apolipoproteins AI and B (apo-AI and apo-B) were
measured by radial immunodiffusion using standards
and plates from Daiichi Pure Chemicals Company. The
CV for apo-AI and apo B were 2.4% and 1.9%, respec-
tively, intra-assay, and 3.8 and 4.3%, respectively, inter-
assay.
Lp(a), was measured by non competitive sandwich-
ELISA method (Immuno AG, Vienna Austria). Lp(a)
glicoprotein phenotype was determined by gel elec-
trophoresis according to Utermann et al. [19] (Immuno
AG, Vienna, Austria). The CV, intra-assay and inter-
assay, was 2.9 and 4.1%, respectively.
Hormone measurements were also centralized. Serum
GH assay was carried out by IFMA (Delfia, Pharma-
cia®) at the University of Milano. Plasma IGF-I was
measured by RIA after acid-ethanol extraction at the
University of Genova [20]. The upper limit of normal
IGF-I levels (mean 93SD) was 366 mg:l for age-
matched adults. Insulin and glucagon levels were mea-
sured by commercial RIA kits (provided by Medgenix
Diagnostics, Belgium and DPC, USA, respectively) at
the University ‘La Sapienza’ of Rome. Intra-assay and
inter-assay CV were below 5 and 8%, respectively, for
all hormone measurements.
2.5. Statistical analysis
Data with multiple observations for each time (GH,
insulin) were quantified by measuring the area under
the curves (AUC) using the trapezoidal method. Areas
and the mean hormonal and lipid levels were compared
using non-parametric statistics (Wilcoxon’s signed rank
test or Mann–Whitney U, as appropriate). Correlation
between continuous variables was investigated by re-
gression analysis. All results are expressed as mean9
SD, unless otherwise stated. Significance is taken as
PB0.05.
3. Results
3.1. Hormonal and metabolic changes induced by
octreotide
Basal serum GH and IGF-I were elevated in all
patients. During octreotide therapy, serum GH levels
(mean of eight samples taken hourly during 7-h saline
infusion) decreased from 14.3931 to 7.5922 mg:l
(median: 60%) (PB0.01). GH AUC (7-h) was
halved (PB0.01). Plasma IGF-I levels (mean of two
samples) decreased from 6659155 to 3549206 ng:ml
(median: 48%); (PB0.01). Nine patients showed a
decrease of mean serum GH levels to below 2 mg:l and
normalized IGF-I levels, while one patient normalized
IGF-I levels even if mean serum GH concentration was
5.5 mg:l.
During octreotide therapy mean insulin and glucagon
concentrations significantly decreased, while glucose
levels (both pre-prandial and post-prandial), signifi-
cantly increased (Table 1). Expressed as 7-h AUC, a
mean insulin decrease of about 40%, a mean glucagon
decrease of about 20% and a mean glucose increase of
11% were observed.
As far as the response to a glucose load is concerned,
during treatment the blood glucose peak at 2 h (4 h
after octreotide administration) was increased in com-
parison with the baseline test (glucose peak: 194.1950
versus 162.4942 mg:dl, PB0.01). Insulin release after
glucose load was significantly reduced during octreotide
therapy with respect to baseline (129989 versus 1559
243 mU:ml, PB0.01).
3.2. Lipids
Before treatment, fasting total cholesterol was 2079
47 mg:dl, ranging from 128 to 291 mg:dl, and being
higher than 200 mg:dl in ten patients. After treatment,
it slightly decreased to 196947 (range from 137 to 305
mg:dl, median: 5.%), being higher than 200 mg:dl
(5.2 mol:l) in seven patients.
Table 1
Effects of 3 months of octreotide therapy (100 mg t.i.d., sc) on
hormonal and metabolic parameters (mean9SD and AUC9SD)
Parameters PBefore therapy Octreotide
354.39206IGF-I (ng:ml) B0.01665.59155
7.5922GH (mg:l)a B0.0114.3931
300299089 B0.016021913283GH, 7-h AUC
(mgmin:l)
47.2926 B0.0129.9921Insulin (mU:ml)a
B0.0119 718911137Insulin, 7-h AUC 11 90498086
(mUmin:ml)
72.2924Glucagon (pgml)a 59.6925 B0.05
30 018910494Glucagon, 7-h AUC 24 120910370 B0.05
(pgmin:ml)
100.4910Glucose (mg:dl)a 112.0916 B0.01
B0.0142 18494480Glucose, 7-h AUC 47 00396686
(mgmin:dl)
a Mean of eight samples taken hourly during 7-h saline infusion.
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Table 2
Fasting lipid, lipoprotein levels and the relative flotation rate, an
index of LDL peak buoyancy, in 20 acromegalic patients before and




207942 207947 196947Total cholesterol
(mg:dl)
84930 98994Total triglycerides 99938
(mg:dl)
125940LDL cholesterol 146943** 125940
(mg:dl)
65913HDL cholesterol 42910*,** 51915*
(mg:dl)
131917*Apo-AI (mg:dl) 140918*175925
89915Apo-B (mg:dl) 84927 79926
19919**13913 14913Lp(a) (mg:dl)
Relative flotation 0.4290.02 0.4090.03* 0.3990.03*
rate (Rf)
a Data are given as mean9SD.
* PB0.05 versus controls.
** PB0.05 versus octreotide.
levels were not modified by octreotide administration.
Slight hypertriglyceridemia was present in two patients
only, and in both triglyceride levels decreased (from 228
to 206 mg:dl, and from 161 to 115 mg:dl).
In respect to normal subjects, there was no significant
difference in the pre-treatment or post-treatment levels
of total cholesterol and triglycerides. HDL cholesterol
levels of untreated acromegalic patients were signifi-
cantly lower than HDL cholesterol levels of normal
subjects (Table 2). The statistical significance was still
present when considering post-treatment HDL values.
Single vertical spin-LDL ultracentrifugation showed
that the physical characteristics of LDL before and
during therapy remained unmodified (Fig. 1). In fact
the relative flotation rate, Rf, was 0.4090.03 before
octreotide treatment and 0.3990.03 after therapy. In
comparison with controls, the LDL particles (both
before and during therapy) in acromegalic patients
appeared different, with a significantly lower Rf (Table
2).
During therapy apo-AI increased and apo-B de-
creased in parallel with HDL and LDL changes (Table
2), but the differences failed to reach statistical signifi-
cance. Just like HDL, apo-AI were significantly lower
in acromegalic patients (both before and after therapy)
in comparison to normal subjects.
No significant correlations were found between these
lipid modifications and GH, IGF-I, insulin, and
glucagon changes. Indeed, a greater decrease of LDL
was observed in patients who did not normalize GH
and IGF-I concentrations in comparison with patients
who did (19913 versus 1928%, PB0.05).
Lp(a) levels were significantly reduced from 19919
to 14913 mg:dl (median:28%) (Table 2). Apo(a)
phenotype distribution in these acromegalic patients is
reported in Table 3. All phenotypes were affected by
octreotide. Both pre-treatment and post-treatment
Lp(a) concentrations were significantly correlated with
pre-treatment (r0.6, PB0.01) and post-treatment
(r0.5, PB0.05) GH concentrations respectively, but
not with IGF-I or insulin levels. Lp(a) percent decrease
observed during therapy, was significantly correlated
with GH percent decrease, (Fig. 2). However, this
correlation was not statistically significant when one
patient who had major modifications of both GH and
Lp(a) is excluded.
3.3. Other findings
Thyroid function tests remained within the normal
range during the entire study period in all patients.
Serum TSH, free T3 and freeT4 were unchanged (TSH:
1.190.7 versus 1.090.8 mU:ml; free T4: 8.495 versus
8.496; free T3 3.591.5 versus 3.491.4). In 12
women, mean 17 b-estradiol levels were 38.9968 on
the day of pre-treatment saline infusion, and 40.7957
Fig. 1. Vertical spin density gradient ultracentrifugation of plasma
lipoproteins in acromegalic patients before (open circles) and during
(closed circles) octreotide therapy.
Octreotide therapy induced a significant decrease of
LDL cholesterol from 142941.1 to 125940 mg:dl
(median: 14%, PB0.05) and a significant increase of
HDL cholesterol from 41.799.7 to 50.6915.2 mg:dl
(median: 22%, PB0.05). The number of patients
with HDL-cholesterol above 50 mg:dl increased from 4
to 9 and the number of patients with LDL-cholesterol
below 130 mg:dl increased from 8 to 13. Triglyceride
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Table 3
Phenotypes of Lp(a): distribution and levels before and after oc-
treotide (mean9SD) in acromegalic patients
No of patients OctreotideBefore therapyPhenotype
mg:dl(% of total)of Apo(a) mg:dl
2 (10)S2 36.1928 22.1917
32.89207 (35) 25.4911S3
8 (40)S4 2.991 2.391
2 (10)S2:S3 16.2910 11.2910
30.51 ( 5) 25.0S2:S4
cant decrease of Lp(a) were observed by Lam et al. [10]
and by Wildbrett et al. [25], in agreement with us, after
6 months of octreotide therapy. No significant change
in LDL cholesterol levels has been previously reported.
As in our study, Lp(a) apart, no correlations between
lipid, and hormonal changes have been reported.
It has been shown that GH is able to increase hepatic
LDL receptor expression, resulting in an accelerated
elimination rate of the LDL particles and subsequent
lowering of LDL cholesterol [26]. The lack of a correla-
tion between hormonal parameters and LDL reduction,
suggests that this modification is not due to the GH
metabolic effects. Other factors, including octreotide,
might be responsible for the LDL reduction here
observed.
The data regarding LDL physical characteristics are
of interest. In fact, the LDL physical properties have
recently attracted a great deal of attention because of
an increased risk of vascular complications associated
to the presence of small and:or dense LDL particles in
both diabetic and non diabetic patients [4,5].
To our knowledge, only a previous paper by Tan et
al. [6] dealt with LDL subfractions distribution in
acromegaly, obtaining similar results. According to this
author, an increased activity of plasma cholesteryl ester
transfer protein (CETP) could contribute to the en-
hanced formation of small dense LDL particles. Other
factors might be involved in modifying the LDL physi-
cal properties in acromegalic patients. Both hyperin-
sulinism and reduced post-heparin lipase activity might
be involved in the development of hyperlipidemia in
acromegaly [6,27–29]. Hyperinsulinism and insulin re-
sistance are associated with the presence of small and:
or dense LDL particles in diabetic patients [30].
the day of control in therapy (P : NS), progesterone
levels non-significantly changed from 3.198.9 to 0.39
0.3.
4. Discussion
Acromegalic patients were characterized by lower
HDL cholesterol levels (and apo-AI) in comparison to
controls. Treatment with octreotide led to remarkable
changes of the plasma lipoprotein parameters with
beneficial effects on several known cardiovascular risk
factors: an increase in HDL cholesterol (22%), a
decrease in LDL cholesterol (14%) and a decrease of
the Lp(a) levels (all phenotypes) being observed. The
study of LDL particles confirmed that acromegalic
patients had smaller and:or more dense LDL particles
in comparison with normal controls. However, the
LDL subfraction distribution remained unmodified
during octreotide therapy, as we have shown for the
first time.
The results on the effects of octreotide on total,
LDL, and HDL cholesterol and on triglyceride concen-
trations are in agreement with the observations previ-
ously made in another multicenter Italian study [3]. In
fact in that study we found a significant decrease of
both total (9%) and LDL cholesterol (18%), and a
slight, but not significant increase of HDL (4%)
cholesterol. In both studies triglyceride levels decreased
only in patients with pre-treatment hypertriglyceridemia
(only two cases in the present series).
Only a few other studies report on serum lipid
changes in acromegalic patients treated with octreotide
[10,21–25]. A decrease of triglyceride levels has been
reported [21–24], mostly in patients who had hyper-
triglyceridemia [22]. The different results with our study
may be explained by the facts that in all the mentioned
series, about one third of patients had diabetes mellitus
(that we have excluded) and also that about 50% of
their patients had moderate hypertriglyceridemia before
treatment. No or minor modifications of triglycerides, a
significant increase of HDL cholesterol, and a signifi-
Fig. 2. Correlation between GH and Lp(a) decreases observed during
octreotide therapy.
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LDL physical characteristics might also be affected
by the hepatic lipase activity. In fact it has been
demonstrated that LDL size is inversely related to the
hepatic lipase activity [31]. Hepatic lipase is low in
acromegalic patients [6,27]. Therefore, the presence of
small and:or dense LDL particles in acromegalic pa-
tients must be determined by factors other than hepatic
lipase. Tan et al. [6] indicated that in acromegalic
patients GH and HDL are the main determinants of
the LDL subclass distribution. The effects of octreotide
on CETP and lipases are not known. However, during
octreotide treatment we did observe a reduction of GH
and an increase of HDL, without any significant effect
on LDL physical properties. Octreotide seems to im-
prove insulin sensitivity [21,32,33]. A reduced insulin
sensitivity is associated with the presence of small and:
or dense LDL particles [30]. The lack of modifications
of the LDL physical properties during octreotide ther-
apy is therefore probably due to the balanced results of
the modifications in the CETP and hepatic lipase activ-
ities, GH levels, HDL levels and insulin sensitivity.
Lp(a) appears to be clearly modulated by GH. The
Lp(a) concentrations in acromegalic patients are usu-
ally increased [10] and octreotide treatment resulted in
a significant reduction of these concentrations, appar-
ently without any regard to the apo(a) phenotype. We
have found, in agreement with Lam [10], a good corre-
lation between Lp(a) and GH, but not IGF-I, modifi-
cations. This lack of a correlation between Lp(a) and
IGF-I levels is consistent with the hypothesis that GH
and IGF-I have different, probably opposing effects on
Lp(a) levels [34], but also suggests a most important
role for GH in the physiological regulation of Lp(a)
expression in respect to IGF-I.
In conclusion, Lp(a) concentrations are high and
directly correlated with GH levels in acromegalic pa-
tients. Octreotide therapy decreases Lp(a) levels by
decreasing GH concentrations. Low HDL cholesterol
levels and a predominance of small and:or dense LDL
particles are also present in acromegalic patients and
could contribute to the high vascular risk of these
patients. Treatment with octreotide is associated with
an increase of HDL levels and a decrease of total
concentrations of LDL. However, this treatment has
no effect on the LDL physical properties.
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